Extended surveillance to assess safety of 9-valent human papillomavirus vaccine

References

• HPV vaccination for cancer prevention: progress, opportunities, and a renewed call to action. A Report to the President of the United States from the Chair of the President’s Cancer Panel. Bethesda (MD): President’s Cancer Panel; 2018.
   Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson HW, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2007;56(RR–2). 1–6. https://pubmed.ncbi.nlm.nih.gov/17380109/
   PubMedGoogle Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, eBocchini Jr JA, Unger ER. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). Atlanta (GA): US Centers for Disease Control and Prevention; 2014 Aug 29.
   Google Scholar
• Petrosky E, Bocchini JA Jr., Hariri S, Chesson HW, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–04.
   PubMed Web of Science ®Google Scholar
• Office of the Director, National Center for Immunization and Respiratory Diseases. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV. Atlanta (GA): US Centers for Disease Control and Prevention; 2016 Nov 29.
   Google Scholar
• Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33(48):6855–64. doi:10.1016/j.vaccine.2015.08.059.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59. doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• Donahue JG, Kieke BA, Lewis EM, Weintraub ES, Hanson KE, McClure DL, Vickers ER, Gee J, Daley MF, DeStefano F, et al. Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6). doi:10.1542/peds.2019-1808.
   PubMed Web of Science ®Google Scholar
• Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T, Naleway A, Klein NP, Baxter R, Belongia E, et al. The vaccine safety datalink: a model for monitoring immunization safety. Pediatrics. 2011;127 Suppl 1:S45–53. doi:10.1542/peds.2010-1722H.
   PubMed Web of Science ®Google Scholar
• Sukumaran L, McCarthy NL, Li R, Weintraub ES, Jacobsen SJ, Hambidge SJ, Jackson LA, Naleway AL, Chan B, Tao B, et al. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): a comparison with the United States population. Vaccine. 2015;33(36):4446–50. doi:10.1016/j.vaccine.2015.07.037.
   PubMed Web of Science ®Google Scholar
• Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279–84. doi:10.1016/j.vaccine.2011.08.106.
   PubMed Web of Science ®Google Scholar
• Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar R. The safety profile of varicella vaccine: a 10-year review. J Infect Dis. 2008;197 Suppl 2:S165–9. doi:10.1086/522125.
   PubMed Web of Science ®Google Scholar
• Groom HC, Smith N, Irving SA, Koppolu P, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, et al. Uptake and safety of hepatitis a vaccination during pregnancy: a vaccine safety datalink study. Vaccine. 2019;37(44):6648–55. doi:10.1016/j.vaccine.2019.09.043.
   PubMed Web of Science ®Google Scholar
• Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barre syndrome found after meningococcal conjugate vaccination in two large cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(12):1359–60. doi:10.1002/pds.3353.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6). doi:10.1542/peds.2019-1791.
   PubMed Web of Science ®Google Scholar
• Moreira ED, Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138(2):e20154387. doi:10.1542/peds.2015-4387.
   PubMed Web of Science ®Google Scholar
• Kuo HK, Fujise K. Human papillomavirus and cardiovascular disease among U.S. women in the National Health and Nutrition Examination Survey, 2003 to 2006. J Am Coll Cardiol. 2011;58(19):2001–06. doi:10.1016/j.jacc.2011.07.038.
   PubMed Web of Science ®Google Scholar
• Joo EJ, Chang Y, Kwon MJ, Cho A, Cheong HS, Ryu S. High-risk human papillomavirus infection and the risk of cardiovascular disease in Korean women. Circ Res. 2019;124(5):747–56. doi:10.1161/CIRCRESAHA.118.313779.
   PubMed Web of Science ®Google Scholar
• Lawson JS, Glenn WK, Tran DD, Ngan CC, Duflou JA, Whitaker NJ. Identification of human papilloma viruses in atheromatous coronary artery disease. Front Cardiovasc Med. 2015;2:17. doi:10.3389/fcvm.2015.00017.
   PubMedGoogle Scholar
• Lo W, Stephens J, Fernandez S. Pediatric stroke in the United States and the impact of risk factors. J Child Neurol. 2009;24(2):194–203. doi:10.1177/0883073808322665.
   PubMed Web of Science ®Google Scholar
• Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3–4):161–72. doi:10.1159/000494291.
   PubMed Web of Science ®Google Scholar
• Vanasse M, Rossignol E, Hadad E. Chapter 121 - Chronic inflammatory demyelinating polyneuropathy. In: Dulac O; Lassonde M, and Sarnat H, editors. Handbook of clinical neurology. Amsterdam: Elsevier; 2013. Vol. 1122013. pp. 1163–69.https://www.sciencedirect.com/handbook/handbook-of-clinical-neurology.
   Google Scholar
• Laughlin RS, Dyck PJ, Melton LJI, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73:39–45. doi:10.1212/WNL.0b013e3181aaea47.
   PubMed Web of Science ®Google Scholar
• Greene SK, Kulldorff M, Yin R, Yih WK, Lieu TA, Weintraub ES, Lee GM. Near real-time vaccine safety surveillance with partially accrued data. Pharmacoepidemiol Drug Saf. 2011;20(6):583–90. doi:10.1002/pds.2133.
   PubMed Web of Science ®Google Scholar
• Perez-Vilar S, Hu M, Weintraub E, Arya D, Lufkin B, Myers T, Woo EJ, Lo A-C, Chu S, Swarr M, et al. Guillain-Barré syndrome after high-dose influenza vaccine administration in the United States, 2018–2019 season. J Infect Dis. 2021;223(3):416–25. doi:10.1093/infdis/jiaa543.
   PubMed Web of Science ®Google Scholar